Factors influencing elevated serum apolipoprotein B48 in diabetic and control participants

British Journal of Biomedical Science

Volumn 71, Issue 4, 2014, Pages 145-150

  Leonard, A ^a   Kyaw Tun, T ^a   Gaffney, P ^a   Sharma, J ^a   Gibney, J ^a   Boran, G ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Apolipoprotein B 48; Diabetes; Post prandial

Indexed keywords

APOLIPOPROTEIN B48; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

APOLIPOPROTEIN B-48; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TRIGLYCERIDES;

EID: 84925223203     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2014.11669979     Document Type: Article

References (49)

1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60 (3): 473-85.
2. Nordestgaard BF, Benn M, Schnor P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298 (3): 299-308.
3. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and the risk of cardiovascular events in women. JAMA 2007; 298 (3): 309-16.
4. Patel A, Barzi F, jamrozik K et al.; Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110 (17): 2678-86.
5. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999; 246 (4): 341-55.
6. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88 (6A): 9H-15H.
7. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990; 82 (5): 1574-94.
8. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Posgrad Med J 2005; 81 (951): 1-6.
9. Reyes-Soffer G, Holleran S, Karmally W et al. Measures of postprandial lipoproteins are not associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res 2009; 50 (9): 1901-9.
10. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48 (6): 1336-42.
11. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988; 29 (7): 925-36.
12. Cohn JS, Johnson EJ, Millar JS et al. Contribution of apoB-48 and apoB-100 (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34 (12): 2033-40.
13. Castro Cabezas M, de Bruin TWA, Kock LAW, de Bruin TW. Postprandial apolipoprotein B100 and B48 in familial combined hyperlipidemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 1994; 24 (10): 669-78.
14. Lemieux S, Fontani R, Uffelman KD, Lewis GF, Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins. J Lipid Res 1998; 39 (10): 1964-71.
15. Batista MC, Welty FK, Diffenderfer MR et al. Apolipoprotein A-I, B-100 and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 2004; 53 (10): 1255-61.
16. Verseyden C, Meijssen S, Cabezas MC. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 2004; 89 (10): 5021-9.
17. Campos H, Khoo C, Sacks FM. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL and LDL from normolipidemic humans. Atherosclerosis 2005; 181 (2): 345-51.
18. Sakai N, Uchida Y, Ohashi K et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J. Lipid Res 2003; 44 (6): 1256-62.
19. Jackson KG, Williams CM. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 2004; 176 (2): 207-17.
20. Kinoshita M, Kojima M, Matushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 2005; 351 (1-2): 115-20.
21. Lamon-Fava S, Diffenderfer MR, Barrett HR et al. Extendedrelease niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28 (9): 1672-8.
22. Otokozawa S, Ai M, Diffenderfer MR et al. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism 2009; 58 (11): 1536-42.
23. Lorec AM, Juhel C, Pafumi Y et al. Determination of apolipoprotein B-48 in plasma by a competitive ELISA. Clin Chem 2000; 46 (10): 1638-42.
24. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultantion. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO, 1999.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Tracher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412-9.
26. Uchida Y, Kurano Y, Ito S. Establishment of monoclonal antibody against human apo B-48 and measurement of apo B-48 in serum by ELISA method. J Clin Lab Anal 1998; 12 (5): 289-92.
27. Wu MS, Johnston P, Sheu WH et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13 (1): 1-8.
28. Hollenbeck CB, Johnston P, Varasteh BB, Chen YD, Reaven GM. Effects of metformin on glucose, insulin and lipid metabolism patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab 1991; 17 (5): 483-9.
29. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17 (10): 1093-9.
30. James AP, Watts GF, Mamo JC. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin resistant subjects. Diabetes Obes Metab 2005; 7 (4): 381-9.
31. Skrapari I, Perrea D, Ioannidis I et al. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not very low-density lipoprotein subfraction levels. Diabet Med 2001; 18 (10): 781-5.
32. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002; 18 (6): 484-90.
33. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with type II diabetes. Diabetologia 2000; 43 (3): 278-84.
34. Shimono D, Kuwamura N, Nakamura Y, Koshiyama H. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes. Diabetes Care 2001; 24 (5): 971.
35. Tan GD, Fielding BA, Currie JM et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 2005; 48 (1): 83-95.
36. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs. glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 2006; 29 (1): 143-8.
37. van Wijk JPH, Castro-Cabezas MC, de Koning EJP, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005; 28 (4): 844-9.
38. Nakano T, Tanaka A, Okazaki M, Tokita Y, Nagamine T, Nakajima K. Particle size of apoB-48 carrying lipoproteins in remnant lipoproteins isolated from postprandial plasma. Ann Clin Biochem 2011; 48 (Pt 1): 57-64.
39. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscl Thromb Vasc Biol 2006; 26 (6): 1357-63.
40. Duez H, Lamarche B, Valero R et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008; 117 (18): 2369-76.
41. Cianflone K, Paglialunga S, Roy C. Intestinally derived lipids: metabolic regulation and consequences. An overview. Atheroscler Suppl 2008; 9 (2): 63-8.
42. Leonard CA. A study of postprandial lipoprotein metabolism and glycaemic control in a population with type 2 diabetes mellitus. PhD Thesis, Trinity College, Dublin, 2010.
43. Philips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000; 148 (2): 283-91.
44. Eriksson JW, Buren J, Svensson M, Olivecrona T, Olivecrona G. Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 2003; 166 (2): 359-67.
45. Battula SB, Fitzsimons O, Moreno S et al. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism? Metabolism 2000; 49 (8): 1049-54
46. Dane-Stewart CA, Watts GF, Pal S et al. Effect of atorvastatin an apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism 2003; 52 (10): 1279-86.
47. Ceriello A, Assaloni R, Da Ros R et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111 (19): 2518-24.
48. Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of shortand long-term simvastatin treatment. Circulation 2002; 106 (10): 1211-8.
49. Kolovou GD, Anagnostopoulou KK, Salpea KD, Daskalopoulou SS, Mikhailidis DP. The effects of statins on postprandial lipemia. Curr Drug Targets 2007; 8 (4): 551-60.